Several other clinical trials demonstrating lack of sufficient clinical activity of bortezomib in patients with metastatic melanoma have also failed to take BRAF mutation status into account (NCT00288041, NCT00580320, NCT01462773, and NCT01078961) [6, 8–10]. Here, BRAF is linked to metastatic melanoma.